Search results for "Static"

showing 10 items of 1528 documents

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

2021

A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m2 on day 1 and 8, plus capecitabine 1000 mg/m2 bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentVinorelbineCapecitabineStable DiseaseInternal medicineCarcinomamedicinebreast carcinomaoral chemotherapymetastasesChemotherapybusiness.industrycapecitabinemedicine.diseaseMetastatic breast cancervinorelbineSettore MED/18 - Chirurgia GeneraleToxicitybusinessBreast carcinomaBiotechnologymedicine.drugResearch Article
researchProduct

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, B…

2013

Oncologymedicine.medical_specialtybusiness.industryFOLFIRINOXHematologymedicine.diseaseGastroenterologyGemcitabineOncologyPancreatic Cancer Stage IVPancreatic cancerInternal medicineMetastatic pancreatic cancermedicineGastrointestinal cancerbusinessmedicine.drugNab-paclitaxel
researchProduct

Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 n…

2018

Oncologymedicine.medical_specialtybusiness.industryHER2 negativeRibociclibHematologymedicine.diseaseMetastatic breast cancerOncologyHormone receptorInternal medicinemedicineFirst line chemotherapybusinessHormoneAnnals of Oncology
researchProduct

OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer

2018

IF 4.942 (2017); International audience

Oncologymedicine.medical_specialtybusiness.industry[SDV.CAN]Life Sciences [q-bio]/Cancer02 engineering and technologyHematology021001 nanoscience & nanotechnologymedicine.diseaseOutcome (game theory)3. Good health[SDV.CAN] Life Sciences [q-bio]/CancerOncology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieInternal medicineCohort0202 electrical engineering electronic engineering information engineeringmedicineNon metastaticAnal cancer020201 artificial intelligence & image processingRadiology Nuclear Medicine and imaging[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie0210 nano-technologybusiness
researchProduct

Patient Reported Outcome in metastatic breast cancer and platinum-resistant recurrent ovarian cancer treated with metronomic cyclophosphamide ± metho…

2021

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseaseMetastatic breast cancerRecurrent Ovarian CancerInternal medicineMedicinePatient-reported outcomeMethotrexatebusinessMetronomic cyclophosphamidePlatinum resistantmedicine.drugSenologie - Zeitschrift für Mammadiagnostik und -therapie
researchProduct

A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastat…

2018

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseasePlaceboMetastatic breast cancerlaw.inventionCapecitabine03 medical and health sciences0302 clinical medicineRandomized controlled triallawTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusiness030217 neurology & neurosurgerymedicine.drugGeburtshilfe und Frauenheilkunde
researchProduct

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Gr…

2021

Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists’ underestimation of their symptoms and spiritual aspects. This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Her care team recommended hormone therapy with abemaciclib plus fulvestrant. Her diarrhea started after 10 days of …

Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorCase ReportDiseaseBreast cancerInternal medicineEstrogen receptorMedicineRC254-282Fulvestrantbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerMetastatic breast cancermedicine.diseaseMetastatic breast cancerAbemaciclibOncologyDetoxifying dietNutraceuticalsHormone therapyIntegrative medicinebusinessmedicine.drugCase Reports in Oncology
researchProduct

Population Pharmacokinetics of Palbociclib in aReal-World Situation

2021

Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacokinetics study of palbociclib in women routinely followed in a cancer center. One hundred and fifty-one samples were analyzed. The sampling times after administration ranged from 0.9 to 75 h and the samples were taken between 1 and 21 days after the beginning of the palbociclib cycle. Palbociclib was determined using a validated mass spectrometry method. The best model that described the concentrat…

Oncologymedicine.medical_specialtypalbociclibPharmaceutical ScienceRenal functionlcsh:Medicinelcsh:RS1-441Population pharmacokineticsAbsorption (skin)Palbociclib030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineLag timepopulation pharmacokineticsInternal medicineDrug Discoverymedicinereal-world situationDosingPostmenopausal womenbusiness.industrylcsh:Rmedicine.diseaseMetastatic breast cancer030220 oncology & carcinogenesisMolecular MedicinebusinessPharmaceuticals
researchProduct

Molecular, Biological and Structural Features of V

2018

Microtubules are important drug targets in tumor cells, owing to their role in supporting and determining the cell shape, organelle movement and cell division. The complementarity-determining regions (CDRs) of immunoglobulins have been reported to be a source of anti-tumor peptide sequences, independently of the original antibody specificity for a given antigen. We found that, the anti-Lewis B mAb light-chain CDR1 synthetic peptide Rb44, interacted with microtubules and induced depolymerization, with subsequent degradation of actin filaments, leading to depolarization of mitochondrial membrane-potential, increase of ROS, cell cycle arrest at G2/M, cleavage of caspase-9, caspase-3 and PARP, …

Oncologytubulinapoptosiscomplementarity-determining regionpeptideOriginal Researchmetastatic melanomamicrotubuleFrontiers in oncology
researchProduct

Molecule non-radiative coupling to a metallic nanosphere: an optical theorem treatment.

2009

The non-radiative coupling of a molecule to a metallic spherical particle is approximated by a sum involving particle quasistatic polarizabilities. We demonstrate that energy transfer from molecule to particle satisfies the optical theorem if size effects corrections are properly introduced into the quasistatic polarizabilities. We hope that this simplified model gives valuable information on the coupling mechanism between molecule and metallic nanos-tructures available for, e.g., surface enhanced spectroscopy signal analysis.

Optical Rotationoptical theoremMetal NanoparticlesSpectrum Analysis RamanMolecular physicsCatalysislcsh:ChemistryInorganic ChemistryComputational chemistryRadiative transferMoleculePhysical and Theoretical ChemistryOptical rotationPhysics::Chemical PhysicsParticle SizeSpectroscopylcsh:QH301-705.5Molecular BiologySpectroscopyPhysicsCouplingenergy transferCommunicationOrganic ChemistryOptical theoremGeneral MedicineComputer Science Applicationsplasmon modeslcsh:Biology (General)lcsh:QD1-999Models Chemicalsurface enhanced spectroscopyParticleGoldQuasistatic processAlgorithmsNanospheresInternational journal of molecular sciences
researchProduct